Ocrelizumab bests interferon for relapsing MS at 2 years

VANCOUVER – Ocrelizumab, a B-cell depleting humanized monoclonal antibody being developed by Hoffman–La Roche, consistently outperformed interferon beta-1a (Rebif) for relapsing multiple sclerosis in...
Source: Family Practice News - Category: Primary Care Source Type: news